Press Releases
- Press Press ReleasesPresentation to Examine the Potential of LAMP Enhancing Antitumor Immunity November 13, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. scientist, Dr. Pratima Sinha, will presentRead more
Immunomic Therapeutics Offers Travel Fund for Clinical Trial Patients
Press ReleasesOctober 11, 2017 07:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company is proud to announce a travel fund for patients enrolledRead moreImmunomic Therapeutics Welcomes New Oncology Advisor
Press ReleasesJuly 31, 2017 07:30 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company is pleased to welcome a new oncology advisor, Duke University’sRead moreAstellas Announces FDA Fast Track Designation for Peanut Allergy
Press ReleasesAstellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions Due to Peanut Allergy TOKYO, Dec. 20, 2016 /PRNewswire/ -- Astellas Pharma Inc.Read moreImmunomic Therapeutics, Inc. Participates in Webcast on Making a Name in Cancer Immunotherapy
Featured Highlights Press ReleasesJune 12, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc., will participate in a BioPharma Dealmakers webcast, sponsored inRead moreIVY and Immunomic Therapeutics to Host Cancer Moonshot Discussion
Press ReleasesBill Hearl and Greg Simon to Examine Lessons from the Cancer Moonshot Initiative May 23, 2017 08:00 AM Eastern Daylight Time WASHINGTON--(BUSINESS WIRE)-- Tomorrow, IVY and Immunomic Therapeutics, Inc. (ITI)Read moreImmunomic Sr. Vice President to Speak at Skin Vaccination Summit 2017 in the Netherlands
Highlights Press ReleasesMay 22, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. (ITI) Senior Vice President of Research and Development Teri Heiland, Ph.D., will present on DNA vaccinesRead more- Highlights Press ReleasesImmunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV) Immunomic exclusively licensed patent portfolio from Annias Immunotherapeutics for use in combination with Immunomic’s investigationalRead more
Immunomic Therapeutics and TRIANNI Sign License Agreement for The Trianni Mouse™
Featured Highlights Press ReleasesImmunomic Therapeutics and TRIANNI Sign License Agreement for The Trianni Mouse™ May 18, 2017 Eastern Standard Time ROCKVILLE, Md. & SAN FRANCISCO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held,Read moreImmunomic Therapeutics (ITI) Named “Company of the Year” by the Tech Council of Maryland
Press ReleasesROCKVILLE, Md., May 16, 2016 /PRNewswire/ -- At the North Bethesda Marriott, Maryland's leading technology and life science companies gathered to celebrate recent successes from the most innovative teams in theRead moreImmunomic Therapeutics Gives Back to Maryland Biotech Community
Press ReleasesNovember 08, 2016 07:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced they are now accepting applications for their Cancer DiscoveryRead moreImmunomic Therapeutics’ Scientific Advisory Board Expansion
Press ReleasesJanuary 05, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces two additions to their Scientific Advisory Board. “We could notRead more